AVADEL PHARMACEUTICALS PLC (NASDAQ:AVDL) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On December 5, 2019, upon the recommendation of its Nominating and Corporate Governance Committee, the Board of Directors (the “Board”) of Avadel Pharmaceuticals plc (the “Company”) appointed Dr. Mark McCamish to join the Board. The Board determined that Dr. McCamish is independent under the listing standards of Nasdaq. Dr. McCamish was also appointed to serve on the Audit Committee of the Board. Effective as of December 5, 2019, the Audit Committee of the Board is composed of Dr. McCamish, Geoffrey M. Glass, Peter Thornton and Dr. Eric Ende. The composition of the Compensation Committee and the Nominating and Corporate Governance Committee remains unchanged.
As a non-employee director, Dr. McCamish will receive cash compensation and an equity award for his Board service in accordance with the Company’s non-employee director compensation practices. Dr. McCamish is not a party to any transaction with the Company that would require disclosure under Item 404(a) of Regulation S-K, and there are no arrangements or understandings between Dr. McCamish and any other persons to which he was selected as a director.
On December 10, 2019, the Company issued a press release announcing Dr. McCamish’s appointment to the Board. A copy of this press release is furnished as Exhibit 99.1 to this report on Form 8-K.
|99.1||Press release issued by the Company on December 10, 2019, furnished herewith.|
AVADEL PHARMACEUTICALS PLC Exhibit
EX-99.1 2 tm19247021_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Avadel Pharmaceuticals Appoints Dr. Mark McCamish to its Board of Directors DUBLIN,…
To view the full exhibit click